JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yokoyama, I.
Right arrow Articles by Nagai, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yokoyama, I.
Right arrow Articles by Nagai, R.

Troglitazone Improves Whole-Body Insulin Resistance and Skeletal Muscle Glucose Use in Type II Diabetic Patients

Ikuo Yokoyama, Katsunori Yonekura, Toshiyuki Moritan, Madoka Tateno, Toshimitsu Momose, Kuni Ohtomo, Yusuke Inoue and Ryozo Nagai

Departments of Cardiovascular Medicine and Radiology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan



View larger version (12K):

[in a new window]
  		FIGURE 1. Schematic representation of 3-compartment FDG tracer kinetic model. k4 is assumed to be 0 in skeletal muscle. Difference between FDG and glucose was calculated to be 1.0 in skeletal muscle cells as reported in human studies. 18FGD-6-P = FDG-6-phosphate.

 


View larger version (19K):

[in a new window]
  		FIGURE 2. GDR and SMGU show significant positive relationship (r = 0.75; P < 0.01).

 


View larger version (19K):

[in a new window]
  		FIGURE 3. Significant positive relationship between GDR and SMGU is more apparent after troglitazone therapy (r = 0.77; P < 0.01).

 


View larger version (29K):

[in a new window]
  		FIGURE 4. FDG PET images of femoral muscle. (A) In patients with type II diabetes before troglitazone therapy, images show irregular and relatively reduced FDG uptake compared with that after therapy and in control subjects. (B) After troglitazone therapy, images show improvement in irregular and relatively reduced FDG uptake, especially in anterior part, but not to level seen in control subjects. (C) In control subjects, images show apparently homogeneous FDG uptake compared with that in patients with type II diabetes.

 




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2001 by the Society of Nuclear Medicine.